Signum Biosciences, 7 Deer Park Drive, Princeton Corporate Plaza, Suite H, Monmouth Junction 08852; 732-329-6344; fax, 732-329-8344. Maxwell Stock, vice president. www.signumbiosciences.com.
Signum Biosciences, which develops compounds designed to fight diseases related to aging, has named Braham Shroot, former CSO of Barrier Therapeutics, as its new CEO. Shroot replaces Gregory Stock, who will remain a member of the board.
The appointment coincides with Signum’s first commercialized skin-care compound, Arazine, which it helped developed with Japan-based pharma firm Rohto Pharmaceutical.
Shroot, who earned his bachelor’s in chemistry and his Ph.D. in organic chemistry from Glasgow University in Scotland, is also a board member of the Wound Healing Society and associate editor of the Journal of Investigative Dermatology. Shroot was chief science officer and vice president of R&D for DFB Pharmaceuticals, a developer of pharmaceuticals for the skin, wound care, and surgical markets. Prior to that he worked for L’Oreal and Galderma.
Marian McLeod, 79, on August 4. She was a professor of speech at TCNJ for 32 years.
Robert Tucker, 92, on July 29. He was a professor of politics at Princeton University and the founding director of the university’s Russian studies program.
Constance Clovis, 68, on July 27. She co-founded the Trenton chapter of the National Junior Tennis League.
Pietro Dalle Nogare, 81, on July 11. , 2010. He was employed by RCA/Sarnoff Center for 52 years.